The number of ongoing clinical studies involving AR targeting is steadily expanding and has included patients with both early and advanced breast cancer and of different subtypes [36–39] (ClinicalTrials.govidentifier: NCT01842321, NCT01889238, NCT02689427, NCT02676986, NCT02457910, NCT02463032, NCT02368691). The gene discussed is AR; the disease is breast cancer.